Search

Displaying results 6201 - 6210 of 10000 in total
  1. Drug

    NRP369

    go.drugbank.com/drugs/DB06384
    Experimental

    NRP369 is an oxycodone derivative under investigation for the treatment of pain (moderate to moderately severe). NRP369 was developed by New River Pharmaceuticals as a backup therapeutic to [NRP290].

  2. Drug

    Xiliertinib

    go.drugbank.com/drugs/DB21453
    Investigational

    Xiliertinib is under investigation in clinical trial NCT02601274 (Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor). Xiliertinib has a monoisotopic molecular weight of 442.21 Da. … The usage of the INN stem '-ertinib' in the name indicates that Xiliertinib is a epidermal growth factor receptor (EGFR) inhibitor.

  3. Drug

    Paltimatrectinib

    go.drugbank.com/drugs/DB21588
    Investigational

    Paltimatrectinib has a monoisotopic molecular weight of 434.13 Da. … Paltimatrectinib is under investigation in clinical trial NCT04901806 (Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors).

  4. Drug

    Hexestrol

    go.drugbank.com/drugs/DB07931
    ApprovedWithdrawn

    A synthetic estrogen that has been used as a hormonal antineoplastic agent.

    Synonyms: Meso-3,4-di(p-hydroxyphenyl)-n-hexaneCategories: Estrogens, Non-Steroidal
  5. Drug

    Ranosidenib

    go.drugbank.com/drugs/DB21727
    Investigational

    Ranosidenib has a monoisotopic molecular weight of 453.12 Da. … Ranosidenib is under investigation in clinical trial NCT06387069 (A Study to Evaluate HMPL-306 in Patients With IDH1- and IDH2-mutated Acute Myeloid Leukemia).

  6. Drug

    Zinc protoporphyrin

    go.drugbank.com/drugs/DB03934
    Experimental

    Synonyms: Protoporphyrin IX containing ZnCategories: Heterocyclic Compounds with 4 or More Rings
  7. Drug

    Pardoprunox

    go.drugbank.com/drugs/DB12061
    Investigational

    Pardoprunox has been used in trials studying the treatment of Early Stage Parkinson's Disease and Advanced Stage Parkinson's Disease. … Pardoprunox is a partial dopamine D2 agonist and noradrenergic agonist with serotonin 5-HT1A agonist properties.

  8. Drug

    DDP-200

    go.drugbank.com/drugs/DB05919
    Experimental

    DDP200 is developed by Dynogen for the treatment of non-incontinent form of overactive bladder (OAB) with particular focus on both male and female patients with urinary frequency, urinary urgency and nocturia

  9. Drug

    Coltuximab ravtansine

    go.drugbank.com/drugs/DB06342
    Investigational

    Coltuximab ravtansine (SAR3419) targets CD19 and is being investigated for the treatment of acute lymphoblastic leukemia (ALL).

  10. Drug

    Nifurizone

    go.drugbank.com/drugs/DB19694
    Experimental

    The usage of the INN stem 'nifur-' in the name indicates that Nifurizone is a 5-nitrofuran derivative. Nifurizone has a monoisotopic molecular weight of 307.09 Da. … The usage of the INN stem '-zone' in the name indicates that Nifurizone is a anti-inflammatory analgesic, phenylbutazone derivative.